Better Health for All
-40
AtriCure's core business delivers exceptional health benefits, focusing on treatments for atrial fibrillation, left atrial appendage management, and post-operative pain, reaching 139,000 patients in 2022.
1
Surgical ablation is associated with a 29% reduction in late mortality, and LAA exclusion reduces thromboembolic events and readmissions.
2
The company's R&D investment was 17.4% of revenue in 2022 and 17.7% in 2021, demonstrating a strong commitment to innovation.
3
However, the 2022 FDA Medical Device Reporting Rate of 0.02% (200 per million) indicates a need for improvement in safety performance.
4
While net price increases were low (0.3% in 2022),
5
there is no evidence of pricing relative to production cost or specific discount programs. The company's commitment to clinical trial diversity and the Women’s Cardiac Health Awareness Program are positive,
6
but specific reach to vulnerable populations is not quantified. AtriCure is evaluating opportunities to reduce EtO concentration levels used in device sterilization,
7
indicating ongoing efforts to mitigate potential negative health externalities. The company does not handle patient health information directly, and while it has policies for data breaches,
8
it does not provide specific metrics on data protection. While the company offers non-opioid pain management solutions,
9
there is no quantified impact on addiction reduction. The company provides training to over 3,000 healthcare professionals,
10
but the scale of this support relative to the overall workforce is not specified. Mental health initiatives are limited to emotional intelligence training for leaders and an employee advocate program, with no broader public or patient-focused programs.
11
Fair Money & Economic Opportunity
0
AtriCure, Inc. is a medical device company.
1
The company does not offer lending, deposit, or other consumer financial services.
2
Therefore, all KPIs related to financial products, services, and customer financial outcomes are not applicable to AtriCure's operations, resulting in a score of 0 for each KPI.
Fair Pay & Worker Respect
20
AtriCure's CEO to median employee pay ratio was 83:1 in 2024.
1
None of the company's employees are represented by a labor union.
2
The company has not experienced any employee fatalities due to work-related injuries or illnesses in its history.
3
An annual assessment concluded that the company has achieved pay parity across gender and ethnicity.
4
The voluntary employee turnover rate has remained consistently below 10% over the last five years.
5
All full-time U.S.-based employees are eligible for medical, dental, and vision insurance.
6
Fair Trade & Ethical Sourcing
0
AtriCure reports zero grievances related to human rights, including forced or child labor, within its supply chain.
1
The company's material control system provides visibility across its supply and distribution chains, allowing lot traceability from raw materials to finished products for all manufactured devices.
2
AtriCure communicates expectations for ethical conduct to its direct suppliers and has revised supplier contracts to include language requiring compliance with its Business Partner Conduct Standards, which cover child labor, forced labor, wages, working hours, and human trafficking.
3
However, the percentage of suppliers covered by these enforceable clauses is not specified. For conflict minerals (3TG), the company identified 472 smelters in its supply chain, with 96% being 'Known Smelters'.
4
It identified 5 smelters sourcing from Covered Countries, and the smelters of tantalum and tin from these countries were identified as conformant.
5
The company cannot conclusively determine the countries of origin of all 3TG or whether they financed armed groups in Covered Countries.
6
Honest & Fair Business
0
The company reported $0 monetary losses from legal proceedings associated with bribery, corruption, or false marketing claims for 2020, 2021, and 2022, and 0 FDA enforcement actions for cGMP violations during the same period.
1
The company's recent Form 10-K filings indicate no financial restatements requiring error correction or recovery analysis.
2
AtriCure has an Anti-Corruption Policy and an Anti-Bribery Anti-Corruption (ABAC) Policy, with a compliance program designed to reduce violations of anti-bribery and anti-corruption laws, and provides annual training to applicable personnel.
3
Multiple channels are available for reporting Code of Conduct violations, including a confidential third-party tool (EthicsPoint) accessible in eight languages, and retaliation against good faith reporters is prohibited.
4
The Board of Directors in 2022 was composed of eight independent directors and the President and Chief Executive Officer.
5
95% of AtriCure’s Class A supplier facilities participate in third-party certification and audit programs for manufacturing and product quality, such as ISO 13485 or ISO 9001.
6
The company engages third-party services for security control evaluations, including penetration testing and independent audits, and participates in the Medical Device Single Audit Program (MDSAP).
7
Kind to Animals
-20
AtriCure adheres to ISO 10993-2 best practices for animal welfare in biocompatibility testing and follows U.S. National Institute of Health guidance for animal testing.
1
This indicates that animal testing is conducted, likely for regulatory purposes, but under established welfare guidelines.
No War, No Weapons
-10
AtriCure's core business is medical devices, with no indication of involvement in arms manufacturing, military contracts, or conflict facilitation, and no dual-use technologies with military applications.
1
The company does not perform individual lobbying or employ registered lobbyists, instead participating in trade associations.
2
AtriCure has no reported surveillance or intelligence activities, nor does it develop or use AI militarily.
3
The company has no exposure to controversial weapons and no peace technology investment ratio is applicable to its core operations.
4
Regarding conflict minerals, AtriCure determined that certain products contain conflict minerals (3TG)
5
and that a portion of these may have originated from Covered Countries.
6
The company does not have sufficient information to conclusively determine the countries of origin for all 3TG.
7
AtriCure does not purchase raw ore or unrefined conflict minerals and conducts no purchasing activities directly in the Democratic Republic of the Congo or adjoining countries,
8
with less than 1% of procurement from conflict regions. The company conducts annual risk-based evaluations of its third-party international distributors
9
and performs a good-faith Reasonable Country of Origin Inquiry of its supply chain.
10
AtriCure has not been subject to an independent private sector audit for its conflict minerals program.
11
In 2022, 100% of employees completed required Code of Conduct training.
12
Planet-Friendly Business
0
AtriCure publishes Environmental, Social and Governance (ESG) Reports, including for 2021 and 2023, which address Sustainability Accounting Standards Board (SASB) disclosure topics for the Medical Equipment and Supplies industry.
1
The company evaluates environmental policies and procedures using ISO 14001 criteria as a guide and is establishing monitoring systems for energy consumption, water usage, and waste management practices.
2
Efforts are underway to demonstrate compliance with the U.S. EPA Toxic Substances Control Act for all products by 2025.
3
The company performs lifecycle analyses for electrical equipment per IEC 60601-1-9.
4
Additionally, service centers have reprocessed and refurbished over 110,000 pounds of reusable equipment since 2018, representing approximately 90% of equipment returned.
5
Ninety-five percent of AtriCure’s Class A supplier facilities participate in third-party certification and audit programs, such as ISO 13485 or ISO 9001.
6
However, specific, quantifiable data for the company's overall Scope 1, 2, and 3 emissions, net-zero targets, or environmental compliance violations are not provided for the entire company, with some data only available for its UK subsidiary.
7
Respect for Cultures & Communities
30
AtriCure has no reported cultural appropriation incidents.
1
The company provides several channels for reporting Code of Conduct violations, including a confidential third-party tool, EthicsPoint, accessible in eight languages, and an open-door policy for its compliance department.
2
The company's Code of Conduct is provided in multiple languages, and EthicsPoint is accessible in eight languages, demonstrating strong local language support.
3
All employees completed required Code of Conduct training in 2022, and all employees participate in annual unconscious bias training and continuing education on other DE&I topics.
4
Safe & Smart Tech
0
AtriCure experienced an unauthorized access to an employee email account on March 8, 2021, which potentially compromised names, addresses, dates of birth, Social Security numbers, financial account information, clinical information, and health insurance claims information for 2,487 individuals.
1
There was no indication of actual viewing or misuse of data.
2
As of February 2026, this incident occurred more than four years ago. The company uses encryption of communications via Secure Sockets Layer (SSL) protocols and encryption of information during storage.
3
Multi-factor authentication is mentioned as a safeguard.
4
AtriCure regularly evaluates safeguards, tests defenses through simulations and penetration tests, and reviews operational policies with third-party experts.
5
The company states it retains personal information only as long as reasonably necessary for its business purpose.
6
AtriCure's data protection policy supports compliance with GDPR, CCPA, and HIPAA, and it has established policies and procedures for timely notifications of cybersecurity threats and data breaches.
7
Users can access, correct, and request deletion of their data, and consent can be withdrawn.
8
Zero Waste & Sustainable Products
0
The provided articles, including AtriCure's 2023 ESG reports, do not contain any specific quantitative data or information related to zero waste and sustainable product metrics.
1
There is no evidence regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education programs.
2